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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARYAmyotrophic lateral sclerosis (ALS) is a late-onset motor neuron disorder. Although its neuropathology is well understood, the cellular
and molecular mechanisms are yet to be elucidated due to limitations in the currently available human genetic data. In this study, we
generated induced pluripotent stem cells (iPSC) from two familial ALS (FALS) patients with a missense mutation in the fused-in sarcoma
(FUS) gene carrying the heterozygous FUS H517Dmutation, and isogenic iPSCs with the homozygous FUS H517Dmutation by genome
editing technology. These cell-derivedmotor neuronsmimicked several neurodegenerative phenotypes includingmis-localization of FUS
into cytosolic and stress granules under stress conditions, and cellular vulnerability. Moreover, exon array analysis using motor neuron
precursor cells (MPCs) combined with CLIP-seq datasets revealed aberrant gene expression and/or splicing pattern in FALS MPCs. These
results suggest that iPSC-derived motor neurons are a useful tool for analyzing the pathogenesis of human motor neuron disorders.INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease resulting in the selective death of motor neurons
(Cleveland and Rothstein, 2001). ALS symptoms are associ-
ated with muscle weakness and paralysis and approxi-
mately 80% of ALS patients die within 3–5 years after
the onset of these symptoms. The prevalence of ALS is
two per 100,000 people per year (Bruijn et al., 2004) and
approximately 10% of patients have a familial history of
the disease (Gros-Louis et al., 2006). Familial ALS (FALS)
is identified by mutations in several genes, including
SOD1, TARDBP and FUS (Chen et al., 2013).
Several efforts including animal and in vitro culture
models have been undertaken to understand the patho-
genic mechanism of ALS. In animal models, neurobiolog-
ical phenotypes of ALS are observed, which are due to
multiple pathogenicmechanisms, including protein degra-
dation, oxidative stress, inflammation, paraspeckle forma-
tion, mitochondrial dysfunction and apoptotic pathways
(Lanson and Pandey, 2012; Nishimoto et al., 2013; Robber-
echt and Philips, 2013; Tsao et al., 2012). In addition, the496 Stem Cell Reports j Vol. 6 j 496–510 j April 12, 2016 j ª2016 The Authouse of recently developed induced pluripotent stem cell
(iPSC) technologies also enables understanding of the
disease pathogenesis (Mattis and Svendsen, 2011; Okano
and Yamanaka, 2014). Indeed, iPSCs have been generated
from ALS patients with mutations in SOD1 (Chestkov and
Vasilieva, 2014; Dimos et al., 2008), TDP-43 (Bilican et al.,
2012; Egawa et al., 2012), C9ORF72 (Almeida et al., 2013;
Sareen et al., 2013) and recent publications of FUS (Lenzi
et al., 2015; Liu et al., 2015; Di Salvio et al., 2015) suggest
a useful tool for pursuing the cellular pathogenesis and
mechanism underlying FALS.
FUS, also known as Translocated in Liposarcoma (TLS), is
a DNA/RNA-binding protein containing a glycine-rich re-
gion, an RNA recognition motif and a nuclear localization
signal (Lattante et al., 2013; Yang et al., 2010). In FALS,
more than50mutations in the FUSgenehavebeen reported
(Lattante et al., 2013). Somemutant FUS proteins form nu-
clear/cytosolic protein aggregations that shift from the nu-
cleus to the cytoplasm (Dormann et al., 2010; Suzuki et al.,
2012; Vance et al., 2013; Zhou et al., 2013). This sequestra-
tionof FUS intoaggregations is thought tobeapotential cue
for the initiation of motor neuron degeneration.rs
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Figure 1. Characterization of iPSCs and Differentiation into Motor Neurons
(A) Human dermal fibroblasts from two ALS patients who carried the FUS H517D heterozygous mutation (C-to-G heterozygous mutation);
the mutation was maintained in the generated iPSCs.
(B) Representative image of immunochemical analysis of pluripotent markers, OCT4, SSEA4 and TRA-1-60. Control, YFE-16; FALS, FALS-2e2.
The same images are shown in Figure S1B. The scale bar represents 200 mm.
(C) Representative karyotypes of the generated FALS1 and FALS2 iPSC lines are shown.
(legend continued on next page)
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In the present study, we generated iPSCs from twoALSpa-
tients carrying theFUSH517Dmutation,healthyvolunteers
and isogenic iPSCs with FUS H517D mutation using the
TALEN system and investigated the multifaceted cellular
phenotypes of their motor neurons in vitro. We differenti-
ated these iPSCs into the motor neuron cell lineage and
observed significant mis-localization of mutant FUS to the
cytosoland theaccumulationof FUS instressgranules under
various stresses,whichhasneverbeen reported forwild-type
FUS protein. Furthermore, using two comprehensive ana-
lyses, exon array combined with previous CLIP-seq data
(Lagier-Tourenne et al., 2012), we identified transcripts
showing aberrant gene expression, which may be involved
in FUS-dependent pathology, even inmotor neuron precur-
sor cells (MPCs) derived from FALS iPSCs. The subsequent
analysis using the IN Cell Analyzer revealed an increase
in neuronal cell death and a decrease in neurite length in
FALS iPSC-derived HB9-positive motor neurons compared
with controls under stress conditions. In contrast, in our
analysis on bIII-TUBULIN-positive neurons, there were
nearly no changes in FUS mis-localization, FUS accumula-
tion in stress granules, occurrence of neuronal cell death,
or neurite length. Thus, the present report describes the
in vitro modeling of human ALS with the FUSmutation to
uncover the pathogenetic history of this disease.RESULTS
Generation of FUS-ALS-iPSCs and Differentiation into
Motor Neurons
We generated FALS iPSCs derived from skin fibroblasts iso-
lated from two FALS patients (Figure S1A and Table S1),
both with a pointmutation in the gene encoding the C-ter-
minal domain of the FUS protein (Akiyama et al., 2016). To
reprogram the skin cells into FUS-ALS-iPSCs, we used
episomal vectors carrying OCT4, SOX2, KLF4, L-MYC,
LIN28 and p53 shRNA. The two ALS patients had a hetero-
zygous C-to-G transition at nucleotide 1,550 (c.1550C>G)
in the exon 15 coding sequence of the FUS gene (hereafter
referred to as patient-1, FALS-e46, FALS-e48, and FALS-e54;
and patient-2, FALS-2e2, FALS-2e3, and FALS-2e23). We
confirmed that FALS iPSCs also harbored the heterozygous
C-to-G point mutation in the FUS gene (Figure 1A) and(D) Representative image of immunocytochemistry for the neural stem
ISLET1). The scale bar represents 20 mm.
(E) Quantitative data of the ratio of each MPC marker-positive cell/H
Tukey’s test).
(F) Representative image of immunocytochemistry for motor neur
(bIII-TUBULIN, MAP2, VGLUT1 and GLUR1). The scale bars represent
(G) Quantitative data of the ratio of each marker-positive cell/bIII-T
Tukey’s test).
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This point mutation causes a single amino acid substitu-
tion (histidine to aspartic acid) at amino acid position
517 in the C-terminal domain of the FUS protein, termed
H517D. Furthermore, we established another control
iPSC line, YFE-16 (Shimojo et al., 2015), in addition to
the two control human iPSC lines, 409B2 and 414C2,
which were established previously (Table S1) (Okita et al.,
2011). These three control lines were derived from two
individuals who were diagnosed as clinically healthy and
did not have the C-to-G point mutation in the FUS gene
(Figure 1A). Importantly, these iPSC lines showed the
typical morphology of colonies similar to human embry-
onic stem cell lines, based on the expression of pluripotent
stem cell markers (SSEA4, OCT4, and TRA-1-60) by immu-
nocytochemical analysis (Figures 1B and S1B; control and
FALS in Figure 1B represented YFE-16 and FALS-2e2 respec-
tively and the same images are shown in Figure S1B),
normal karyotypes by the G-band staining method (Fig-
ure 1C) and no exogenous transgene expression by qRT-
PCR (Figure S1C) or oriP genomic PCR (Figure S1D). We
also confirmed the pluripotency of differentiation poten-
tials into three germ layers (Figure S1E). In addition, we
generated isogenic iPSCs with FUS H517D homozygous
mutation (hereafter referred to as FUSH517D/H517D-1, -2,
and -3) using the TALEN genome editing systems on
409B2 control iPSCs (Figure S2).
All iPSCsweredifferentiated intoneural lineages including
motor neurons based on a previously described protocol but
with slightmodifications (Bilican et al., 2012;Chambers and
Fasano, 2009; Egawa et al., 2012; Hester et al., 2011; Hu and
Zhang,2009; Imaizumietal., 2015;Nizzardoetal., 2010; Sur-
macz et al., 2012; Matsumoto et al., 2016). The iPSCs were
transferred into a suspension culture to form the neuro-
sphere in neural progenitor maintenance media containing
retinoic acid and the hedgehog signaling activator, pur-
morphamine, to promote the commitment of MPCs. All
MPCs were constructed from motor neuron progenitor
marker, OLIG2 and SOX2 double-positive cells, and an early
markerofmotorneurondifferentiation, ISLET1positive cells
(Figure 1D). Quantitative analysis for the ratio of marker
expression using IN Cell Analyzer revealed that there was
no significant difference in the differentiation ratio between
control, FALS, and FUSH517D/H517D MPCs (Figure 1E). MPCscell marker (SOX2) andmotor neuron progenitor markers (OLIG2 and
oechst-positive cell (n = 3 independent experiments; means ± SD;
on markers (HB9, ISLET1 and SMI32) and other neural markers
60 mm.
UBULIN-positive cell (n = 3 independent experiments; mean ± SD;
rs
were passaged twice and then adhered on poly-ornithine/
laminin-coated plates. Neurons were differentiated after
20 days in adherent culture. These neuronal cell popu-
lations contained motor neurons (i.e., HB9, ISLET1 and
SMI32), glutamatergic neurons (i.e., VGLUT1) and gluta-
mate-responsive neurons (i.e., GLUR1) (Figure 1F) and
there was no significant difference in the ratio of these
markers between control, FALS, and FUSH517D/H517Dneurons
(Figure 1G).
Aberrant Gene Expression in FALS Motor Neuron
Progenitor Cells
We performed exon array analysis using an Affymetrix
GeneChip Human Exon 1.0 ST Array to analyze RNA pro-
files in control and FALS-derived MPCs, which efficiently
differentiate into motor neurons. We compared 18,738
genes using core probes to observe fold changes (FCs) in
gene expression between the three control and six FALS-
derived cell types. A scatterplot of FCs showed a very
high correlation coefficient of more than 0.9, suggesting
our in vitro culture model was stable regarding their
transcriptome. Next, we prepared a list of FUS-regulated
genes, which were differentially expressed for each cell,
by filtering the gene-level signal intensities with Bayes
statistics p values <0.001. Of the 159 differently expressed
genes we identified, 124 genes were upregulated and 35
genes were downregulated in FALS MPCs as summa-
rized in plots and a heatmap (Figures 2A and 2B). We
analyzed the Gene Ontology (GO) terms (Figure 2C) of
the genes, including SLITRK4, DST, GNAO1, ALCAM,
NFASC, NEUROD4 and ONECUT2 that were aberrantly ex-
pressed in FALS-derived cells. We found that these genes
were associated with neuron differentiation, neuron devel-
opment and cell adhesion and were enriched compared
with the profiles of control MPCs (Aruga and Mikoshiba,
2003).
We reanalyzed a previous FUS CLIP-seq (crosslinking
and immunoprecipitation, followed by high-throughput
sequencing) dataset (Lagier-Tourenne et al., 2012) to deter-
mine whether this gene regulation is involved in direct
regulationof the FUSprotein.Among10,159FUSCLIP clus-
ters, wedefined 1,558 geneswith tagnumberR20 andpeak
height R10; approximately 75% were located in intronic
sequences (Figure 2D), which is consistent with previously
reported FUS binding sites. We found that 23 genes were
significantly overlapped using the exon array of 159 genes
and potential FUS targets, as well as 1,558 genes based
on the CLIP-seq dataset (Figures S3A, S3B, and Table S2).
Most of these differently expressed genes were validated
by qRT-PCR analysis (Figure 2E), indicating consistency
between qRT-PCR and exon array analyses (Table S3).
We also analyzed the alternative splicing changes in con-
trol and FALS MPCs by exon array. We identified alteredStemexpression of exons between control and FALS MPCs
including RSU1 (Ras suppressor protein 1), RPH3AL (rab-
philin 3A-like) and EFCAB13 (EF-hand calcium binding
domain 13), which had differences in expression levels on
the core probes (Figure 3A). To validate these results by
semi-quantitative RT-PCR assay (Figure 3B), we designed
theprimers flanking the splicing target exons in these genes
and validated alternative splicing changes using total RNA
obtained from tertiaryMPC-specific cells by semi-quantita-
tive RT-PCR analysis. As expected, these three genes showed
dramatic splicing changes in FALS MPCs (Figure 3C). To
confirm whether the splicing changes between control
and FALS-derived cells depend on the mutation of the FUS
protein, we analyzed the splicing patterns of these three
genes in the MPCs derived from FUSH517D/H517D-iPSCs
carrying the FUS H517D homozygous mutation. We
confirmed that differential splicing changes also occur
in the RPH3AL and EFCAB13 genes between control
and FUSH517D/H517D MPCs (Figures 3D and S3C). Semi-
quantitative analysis of splicing variants revealed that
FUSH517D/H517D MPCs express higher levels of the RPH3AL
377-bp band than 409B2 control MPCs, but express similar
levels of RSU1 and EFCAB13 splicing bands (Figure 3E).
These results suggest that aberrant gene expressions and/or
splicing changes are associated partially with mutant FUS.
Mutant FUS Is Localized in Stress Granules under Stress
Conditions
The H517D mutation in FUS lies in a nuclear localization
signal (NLS) (Figure 4A). Previous reports revealed that
the FUS protein localizes to the nucleus; however, the
mutations in the NLS sequences of the FUS protein cause
mis-localization in the cytoplasm, even under normal con-
ditions. To address the possibility that the FUS protein from
FALS iPSC-derived cells harboring the H517D mutation
also mis-localizes to the cytoplasm, we performed immu-
nocytochemical analysis. The data confirmed that there
is cytoplasmic mis-localization of the FUS protein in FALS
and FUSH517D/H517D iPSCs (Figure 4B) and we determined
the ratio of cytosolic FUSusing INCell Analyzer (Figure 4C).
The FUS proteins in FALS and FUSH517D/H517D iPSC-derived
neuronal lineage cells (Figures 4D and 4E) andHB9-positive
motor neurons (Figures 4D and 4F) were also mis-localized
into cytosol. In addition, we performed biochemical anal-
ysis to measure the expression levels of FUS mRNA.
Control, FALS and FUSH517D/H517D MPCs and neurons
expressed similar levels of the FUS gene (Figure S4).
It has been reported that mutant FUS localizes into cyto-
plasmic stress granules (SGs) upon various stimuli (Aulas
et al., 2012; Bentmann et al., 2012; Vance et al., 2013).
SGs are cytosolic structures that transiently form upon
exposure of cells to environmental stress, such as heat,
oxidative stress, orhypoxia functions in the cellular defenseCell Reports j Vol. 6 j 496–510 j April 12, 2016 j ª2016 The Authors 499
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E
Figure 2. Exon Array Analysis Using MPCs and Comparison with FUS CLIP-Seq
(A) Scatterplot analysis of gene expression using control and FALS MPCs. A total of 124 genes were upregulated (blue) and 35 were
downregulated (red) in FALS MPCs compared with control MPCs.
(B) The heatmap of correlation coefficients.
(C) Major GO terms showed both increases and decreases in gene expression in FALS versus control MPCs.
(D) Reanalysis of previously reported CLIP-seq (Lagier-Tourenne et al., 2012).
(E) Quantitative RT-PCR analysis of the expression levels for eight randomly selected genes in control and FALS iPSC-derived MPCs. Solid
and hatched bars show qRT-PCR and exon array data, respectively (n = 3–6 independent samples; mean ± SD; Dunnett’s test).
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Figure 3. Alternative Splicing Analysis
on MPCs
(A) The plots of the expression levels in exon
probes. Red and blue lines show control and
FALS expression levels, respectively. The
yellow arrows show the change points of
splicing between controls and FALS in each
gene.
(B) RT-PCR of splicing variants in RSU1,
RPH3AL and EFCAB13 in iPSC-derived MPCs.
The PCR cycle validated the PCR cycle
numbers.
(C) Schematic figure of alternative splicing
in each gene (left) and the measurement of
the expression level of each of the spliced
bands in (B) (right) (n = 3–6 independent
samples; mean ± SD; *p < 0.05; ***p <
0.001; Student’s t test).
(D) RT-PCR of splicing variants in RSU1,
RPH3AL and EFCAB13 in 409B2 and
FUSH517D/H517D-1 iPSC-derived MPCs.
(E) Expression levels of each of the spliced
bands in (D) (n = 3 independent experi-
ments; mean ± SD; *p < 0.05; Student’s
t test).against stress, as well as translational repression of a subset
of mRNAs (Nishimoto et al., 2010). We induced oxidative
stress in iPSCs and iPSC-derived neurons by treatment
with 0.5 mM sodium arsenite for 60 min to observe the
formation of SGs using anti-G3BP (Ras GTPase-activating
protein-binding protein) as a marker of SGs for immunocy-
tochemistry. First we found that FUS proteins from FALS
and FUSH517D/H517D iPSCs and iPSC-derived neurons leak
and formaggregates in the cytosol, and that their aggregates
co-localizewith SGs (Figure S5A). In contrast, wild-type FUS
remained in the nucleus and did not form G3BP-positive
cytoplasmic granules (Figures 5A and 5F). Next, we deter-
mined the number of all SGs and FUS-positive SGs per
OCT4-positive iPSCs or HB9-positive motor neurons using
IN Cell Analyzer. The number of all SGs in iPSCs wasStemunchanged in all lines (Figure 5B); however, the levels
of FUS-positive SGs are significantly higher in FALS- and
FUSH517D/H517D-iPSCs than in controls (Figure 5C). We
next examined similar assays in neuronal lineages. Impor-
tantly, we confirmed that the number of neuronal cell pop-
ulations andall SGs in thedifferentiating cells inour culture
was not significantly changed among all the lines (Figures
5D, 5E and 5G). FALS- and FUSH517D/H517D-iPSC-derived
neuronal lineage cells and HB9-positive motor neurons
showed higher levels of FUS-positive SGs than did controls
with significant changes (Figures 5H and 5I). We obtained
similar results under the condition of 44C heat shock
(Figures S5B–S5E). In addition, FALS iPSC lines expressed
both H517D-mutant and normal FUS; therefore, we used a
transient expression assay to confirm whether the H517DCell Reports j Vol. 6 j 496–510 j April 12, 2016 j ª2016 The Authors 501
mutant FUS protein is localized into cytoplasmic SGs under
stress conditions. The 293T cell lines were transfected with
plasmids encoding either wild-type FUS or H517Dmutated
FUS (Figure S5F). Expectedly, only the H517D FUS mutant
was co-localized with G3BP-positive SGs under the treat-
ment with arsenite but not wild-type FUS, reflecting our
observation in FUS iPSC lines (Figure S5G).
Stress Vulnerability in FALS Motor Neurons
While ALS is an adult-onset neurodegenerative disease
that specifically targets motor neurons, GO analysis and
overlapping genes with CLIP-seq predicted that FALS mo-
tor neurons are involved in neural development (Table
S2). To address the possibility that FALS iPSC-derived
neurons display any defects of neuronal maturation, we
measured neurite length on motor neurons. Neural cell
populations derived from iPSCs included various neuronal
subtypes. Therefore, to label only motor neurons, HB9-
venus reporter lentivirus (HB9:Venus) (Shimojo et al.,
2015) was infected into the iPSC-derived cells. Motor
neurons were visualized by Venus fluorescent protein (Fig-
ure 6A); we identified motor neurons labeled by the Venus
fluorescent protein with the anti-GFP antibody to deter-
mine the length of neurites by IN Cell Analyzer (Figure 6B).
As a result, there were no differences between controls,
FALS, and FUSH517D/H517D-derived bIII-TUBULIN-positive
neurons under all conditions: unstressed, sodium arsenite
treatment and glutamate treatment (Figure 6C). In
HB9:Venus-positive motor neurons, however, FALS and
FUSH517D/H517D neurons showed significantly shorter neu-
rites than controls by treatment with both sodium arsenite
and glutamate (Figure 6D). These results suggest that FALS-
derived neurons might show not only neuronal matura-
tion (in this case, neurite maintenance) but also cellular
vulnerability especially in motor neurons. Therefore, we
next pursued the cell viability of FALS-derived neurons
and HB9-positive motor neurons under normal and stress
conditions by immunostaining with cleaved-CASPASE3,
which is a marker for apoptosis (Figure 7A). In all neurons
labeled with bIII-TUBULIN, we found significant differ-
ences between control and FUSH517D/H517D lines; this
may be due to homozygous mutation of FUS protein (Fig-
ure 7B). However, we were unable to confirm this as a
single population of the FALS line also has a significant
change. On the other hand, in HB9-positive motor neu-
rons, the changes in the apoptotic cell population were
much greater between control and all FALS and
FUSH517D/H517D lines (Figure 7C). These results suggest
that iPSC-derived HB9-positive motor neurons with FUS
H517D mutation are vulnerable to stress and even with
normal conditions rather than other types of neurons,
this phenomenon reflects the ALS-like malady phenotype.
Therefore we conclude that our in vitro FALS model is a502 Stem Cell Reports j Vol. 6 j 496–510 j April 12, 2016 j ª2016 The Authouseful tool to pursue the mechanism underlying the dis-
ease phenotype and treatment.DISCUSSION
In the present study, we established ALS-specific human
iPSCs from two patients with a point mutation in the FUS
gene and isogenic iPSCs with FUS H517D homozygous
mutations derived from healthy 409B2 iPSCs using the
TALEN genome editing system. In addition, we differenti-
ated into patient derived neurons to observe the disease
history of FALS during neuronal differentiation in vitro.
FALS-derived motor neuron lineage cells and HB9-positive
mature motor neurons showed several ALS-related pheno-
types such as neuronal cell death, pathological cellular
structure and altered gene regulation, including steady-
state transcript levels and alternative splicing. Our
in vitro model may thus enable an investigation into the
correlations between the molecular pathophysiology of
ALS and various cell biological phenomena.
RNA-mediated mechanisms in ALS originated from the
first discovery of ubiquitinated TDP43 protein, which is an
RNA-binding protein (Neumann et al., 2006). Subsequent
studies found the mutation in this gene among FALS (Rick-
etts et al., 2014; Rutherford et al., 2008; Sreedharan et al.,
2008). TDP43-containing protein inclusions in cells ulti-
mately came to be recognized as a pathological hallmark
in ALS and frontotemporal lobar degeneration (FTLD). The
other RNA-binding protein, the FUS/TLS protein coding
gene, also contains potential causative mutations in FALS
and in FTLD (Kwiatkowski et al., 2009; Vance et al., 2009).
In the present study, the mutant FUS protein was co-local-
ized with the stress marker protein G3BP in our cultured
iPSCs, HB9-positive motor neurons derived from them,
and fibroblast cell line overexpressing FUS protein respond-
ing to stress conditions, arsenite and heat shock (Figures 5F
and S5). In general, the stress granule is a mechanism for
avoiding stress and has been implicated in the cellular stress
defense. These granules are in equilibrium between assem-
bly and disassembly to manage correct gene regulation
with cellular conditions. One such pathological hypothesis
considers thatonce this equilibriumisdisrupted, these stress
granules form irreversible protein inclusions, named ‘‘path-
ological aggregates.’’ In our in vitromodel, we observed that
FUS mutant proteins localize to SGs in iPSC-derived HB9-
positive motor neurons, even under unstressed conditions;
the co-localization of FUS and G3BP has not been observed
in wild-type cells expressing normal FUS. This suggests the
possibility that over-migration of FUS into SGs potentially
causes aberrant gene expression and/or splicing, and that
thesegranulesmayeventually formpathological aggregates,
leading to neuronal cell death.rs
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Figure 4. FUS Localization in iPSCs and iPSC-Derived Neurons
(A) Schematic diagram of FUS. The H517D mutation is located in the nuclear localization signal; RRM, RNA recognition motif; R/G, R/G rich
region; Z, zinc finger domain.
(B) Representative images of immunocytochemistry for FUS in iPSCs. Arrowheads indicate cytosolic FUS. The scale bar represents 20 mm.
(legend continued on next page)
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Figure 5. FUS Protein Localization into
Stress Granules
(A) Representative images of immunocyto-
chemistry for SG in iPSCs under 0.5 mM sodium
arsenite stress conditions. FUS in FALS and
FUSH517D/H517D iPSCs co-localized with the
SG marker G3BP (arrowhead), whereas FUS in
control iPSCs remained in the nucleus. The
scale bar represents 20 mm. In (A)–(I) images
or graphs, Arsenite means addition of 0.5 mM
sodium arsenite, 1 hr treatment.
(B) Quantitative data of the number of SGs per
OCT4-positive cell in iPSCs (n = 3 independent
experiments; mean ± SD; Dunnett’s test).
(C) Quantitative data of the number of FUS-
positive SGs per OCT4-positive cell in iPSCs
(n = 3 independent experiments; mean ± SD;
*p < 0.05, **p < 0.01; Dunnett’s test).
(D) Representative images of immunocyto-
chemistry for bIII-TUBULIN-positive neurons.
The scale bar represents 20 mm.
(E) Quantitative data of the percentage ofbIII-
TUBULIN-positive neurons (n = 3 independent
experiments; mean ± SD; Dunnett’s test).
(F) Representative images of immunocyto-
chemistry for SG in iPSC-derived neurons under
0.5 mM sodium arsenite stress conditions. FUS
co-localized with the SG marker G3BP (arrow-
head). The scale bar represents 20 mm.
(G) Quantitative data of the number of SGs per
Hoechst-positive cell in iPSC-derived neurons
(n = 3 independent experiments; mean ± SD;
Dunnett’s test).
(H) Quantitative data of the number of
FUS-positive SGs per Hoechst-positive cell in
iPSC-derived neurons (n = 3 independent
experiments; mean ± SD; *p < 0.05, **p <
0.01; Dunnett’s test).
(I) Quantitative data of the number of
FUS-positive SGs per HB9-positive cell in iPSC-
derived neurons (n = 3 independent experi-
ments; mean ± SD; *p < 0.05, **p < 0.01;
Dunnett’s test).FUS binds to DNA as well as to RNA and regulates the
expression of many transcripts in multiple steps of the
gene regulation process (Dormann and Haass, 2013). In(C) Quantitative data of the percentages of cytosolic FUS ratio per OCT4
**p < 0.01; Dunnett’s test).
(D) Representative images of immunocytochemistry for FUS in iPSC-
represents 20 mm.
(E) Quantitative data of the percentage of cytosolic FUS ratio per H
experiments; mean ± SD; *p < 0.05, **p < 0.01; Dunnett’s test).
(F) Quantitative data of the percentage of cytosolic FUS ratio per HB
ments; mean ± SD; **p < 0.01; Dunnett’s test).
504 Stem Cell Reports j Vol. 6 j 496–510 j April 12, 2016 j ª2016 The Authothis study, we used FALS MPCs efficiently oriented into
neuronal lineages including HB9-positive motor neurons
to observe altered gene regulation in FALS-derived cells-positive cells in iPSCs (n = 3 independent experiments; mean ± SD;
derived neurons. Arrowheads indicate cytosolic FUS. The scale bar
oechst-positive cell in iPSC-derived neurons (n = 3 independent
9-positive cell in iPSC-derived neurons (n = 3 independent experi-
rs
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Figure 6. Shorter Neurites in FALS iPSC-
Derived Motor Neurons
(A) Representative images of HB9::Venus-
positive living motor neurons. The scale bars
represent 50 mm.
(B) Representative images of immunocyto-
chemistry for HB9::Venus-positive motor
neurons with anti-GFP antibody. The scale
bar represents 20 mm. In (B)–(D) images
or graphs, Arsenite means 1.0 mM sodium
arsenite, 1 hr treatment; Glutamate means
1.0 mM glutamate, 24 hr treatment.
(C) Quantitative data of the neurite length
of bIII-TUBULIN-positive neurons (n = 3
independent experiments; mean ± SD; Dun-
nett’s test).
(D) Quantitative data of the neurite length
of GFP-positive motor neurons (n = 3 inde-
pendent experiments; mean ± SD; **p <
0.01; Dunnett’s test).and to discover an early disease-related diagnostic marker.
FUS has been shown to associate with RNA polymerase II
and TFIID, thereby participating in the general transcrip-
tional regulation process (Bertolotti et al., 1996). In addi-
tion, FUS binds to TBP and TFIID to repress transcription
by RNAPIII, suggesting that FUS controls the cross-regula-
tion between RNA polymerases (Tan and Manley, 2010).
Recent studies, however, have shown that the recruit-
ment of FUS proteins to promoter regions with lncRNA
represses transcription (Wang et al., 2008). Further-
more, FUS binding to the antisense RNA transcribed by
RNAPIII from promoter regions downregulates transcrip-
tion (Ishigaki et al., 2012). These past studies suggestStemthat FUS regulates transcriptional repression by various
mechanisms in specific target genes. This finding could
reflect our observations from our microarray assay that
78% (124 out of 159 genes) of the significantly changed
genes in transcript levels are upregulated in FALS MPCs.
Furthermore, with more specific analysis that focused on
FUS direct targets that we defined by using the CLIP-seq
dataset, we found that 95.6% of genes (of 23 genes) are
upregulated in FALS.
In one proteomics study, FUS/TLS proteins were also
identified as general splicing factors, which may be an
early stage of the splicing process (Hartmuth et al.,
2002). Our exon array analysis also revealed aberrantCell Reports j Vol. 6 j 496–510 j April 12, 2016 j ª2016 The Authors 505
AB
C
Figure 7. Enhanced Apoptosis in FALS
iPSC-Derived Motor Neurons
(A) Representative images of immuno-
cytochemistry for apoptotic HB9-positive
motor neurons using markers for apoptosis
(cleaved-CASPASE3), immature neurons
(bIII-TUBULIN), and motor neurons (HB9).
Arrowheads indicate HB9 positive cells.
The scale bars represent 20 mm. In (A)–(C)
images or graphs, Arsenite means 0.5 mM
sodium arsenite, 1 hr treatment; Glutamate
means 3.0 mM glutamate, 24 hr treatment.
(B) Quantitative data of the ratio of
cleaved-CASPASE3-positive cells in bIII-
TUBULIN-positive neurons (n = 3 indepen-
dent experiments; mean ± SD; *p < 0.05,
**p < 0.01; Dunnett’s test).
(C) Quantitative data of the ratio of
cleaved-CASPASE3-positive cells in HB9-
positive motor neurons (n = 3 independent
experiments; mean ± SD; *p < 0.05, **p <
0.01; Dunnett’s test).gene splicing events in RSU1, RPH3AL, and EFCAB13 genes
in the FALS patients. Of these, aberrant RNA process-
ing of RPH3AL was also confirmed by our isogenic
FUSH517D/H517D lines, suggesting the direct effects of FUS
H517D mutation. However, in the other two alternative
exons, we did not detect significant differences between
control and isogenic FUSH517D/H517D lines, suggesting
that FUS H517D mutation is not likely to have direct ef-
fects on their splicing regulation. RPH3AL is an associated
protein of RAB3A (Haynes et al., 2001) and RAB27A (Fu-506 Stem Cell Reports j Vol. 6 j 496–510 j April 12, 2016 j ª2016 The Authokuda, 2003) and regulates exocytosis in dense-core gran-
ules from endocrine cells (Haynes et al., 2001). In addition,
mutant RPH3AL is mis-localized throughout the cytosol,
whereas WT-RPH3AL is localized in the distal portion of
the neurites (Fukuda et al., 2004). To date, there has been
no reports of functional analyses of products from each
alternative splicing event in these three genes. This may
be involved in the pathological features of FUS-mediated
pathologies and may also be useful as early diagnostic
markers for ALS. Our iPSC model for FALS may thusrs
represent a useful tool for observing gene expression levels
in themotor neuron lineage, as gene expression analysis in
motor progenitor cells oriented into HB9-positive motor
neurons cannot be achieved using conventional disease
models.
We also addressed whether pathological features
observed in other ALS models are observed in our in vitro
FALS model. Motor neurons in patients with sporadic ALS
express abundant unedited GLUA2 forms in the AMPA re-
ceptor subunit (Kawahara et al., 2004; Kwak et al., 2010),
but the unedited GLUA2 form in FALS MPCs and neurons
derived from iPSCs was not detected (Figure S6). ER stress is
increasingly recognized as an important pathway leading
to cell death in animal and cellular disease models based
on mutant SOD1 (Atkin et al., 2006; Saxena et al., 2009),
andmutant FUS proteins would also be predicted to induce
ER stress and to interact with protein disulfide isomerase,
similar to mutant SOD1 (Farg et al., 2012). In this study,
however, the expression of ER stress-related genes (BIP,
CHOP, spliced XBP1, CASP4, and ASK1) almost did not
change in FALS and FUSH517D/H517D MPCs and neurons
(Figure S7).
Our study showed that neurite length and the ratio of
apoptotic cells in FALS- and FUSH517D/H517D iPSC-derived
neurons were the same as in control motor neurons.
With several stresses especially in glutamate treatment,
however, FALS- and FUSH517D/H517D HB9-positive motor
neurons exhibited shorter neurites and an increased
cleaved-CASPASE3-positive cell ratio compared with con-
trol HB9-positive motor neurons. These results suggest
that FALS iPSC-derived motor neurons are vulnerable
to oxidative and excitatory stresses and there is a possibil-
ity that these phenomena are relevant to ALS-like phe-
notypes. We thus determined that these ALS patient-
specific iPSC-derived motor neurons recapitulate disease
phenotypes.
Recently, other groups also established in vitro FUS
iPSCs models showing the inclusion of the stress granule
of FUS mutant proteins (Lenzi et al., 2015; Liu et al.,
2015). In addition to these findings, we observed addi-
tional ALS-like phenotypes and motor neuron vulnera-
bility under some stress conditions and discovered
potential biologically relevant aberrant gene expressions.
Importantly, these events are also confirmed by the use
of genome editing technology to generate isogenic
mutant FUS H517D, suggesting that the present in vitro
FALS model is able to recapitulate the ALS-like pheno-
types. Based on these results, our mutant FUS-associated
iPSC-derived HB9-positive motor neurons can be added
to the list of model systems that may provide general
tools for use in the analysis of the pathogenic process
and drug screening studies in human motor neuron
disorders.StemEXPERIMENTAL PROCEDURES
Isolation ofHuman Skin Fibroblasts andGeneration of
iPSCs
The 409B2 and 414C2 iPSCs were kindly provided by Dr. Shinya
Yamanaka (Okita et al., 2011). A skin-punch biopsy from a healthy
24-year-old Japaneseman obtained after written informed consent
(Keio University School ofMedicine) was used to generate the con-
trol YFE-16 (Shimojo et al., 2015) iPSCs. FALS-1 and FALS-2 iPSCs
were generated from a 39-year-old Japanese man and 43-year-old
Japanese man, respectively. All the human iPSC clones were estab-
lished by episomal vector transduction of transcription factors
(SOX2, OCT4, KLF4, L-MYC, LIN28 and short hairpin RNA of
p53) into human dermal fibroblasts (Okita et al., 2011). The cells
were evaluated as described previously (Egawa et al., 2012; Mu¨ller
et al., 2011; Okita et al., 2011). All the experimental procedures for
skin biopsy and iPSC production were approved by the Keio Uni-
versity School of Medicine Ethics committee (approval number,
20080016) and Tohoku University School of Medicine Ethics com-
mittee (approval number, 2010-306).
Motor Neuron Differentiation
Motor neuron differentiation of iPSCs was performed as previ-
ously described with slight modifications (Imaizumi et al., 2015).
Briefly, iPSCswere exposed to amedium including 3 mMdorsomor-
phin (Sigma), 3 mM SB431542 (Tocris Bioscience), and 3 mM
CHIR99021 (Stemgent) over 5 consecutive days. Next, iPSCs
were detached from feeder layers and then enzymatically dissoci-
ated into single cells. The dissociated cells were cultured in suspen-
sion in media hormone mix (MHM) (Okada et al., 2008) including
2% B27 supplement (Life Technologies), 2 ng/ml basic fibroblast
growth factor (PeproTech), 3 mM CHIR99021 (Stemgent), 2 mM
SB431542 (Tocris Bioscience), 10 mMY27632 (Wako), 1 mMretinoic
acid (Sigma), 1 mM purmorphamine (Calbiochem), and 10 ng/ml
recombinant human leukemia inhibitory factor (Millipore) for
5–24 days to allow the formation of MPCs. MPCs were passaged
repeatedly by dissociation into single cells followed by culture in
the same manner. Typically, MPCs at three passages were used
for analysis. The starting cell density was 1 3 104 cells/ml in pri-
mary MPC culture and 1 3 105 cells/ml in secondary and tertiary
MPC cultures. For terminal differentiation, dissociated MPCs
were allowed to adhere to poly-L-ornithine- and laminin-coated
dishes with 5 3 104 cells/well in 96-well plate in MHM/B27
including 13 N2 supplement (Gibco), 13 GlutaMAX (Gibco),
10 ng/ml recombinant human brain-derived neurotrophic factor
(R&D Systems), 10 ng/ml recombinant human glial cell line-
derived neurotrophic factor (R&D Systems), 50 ng/ml recom-
binant hSHH (R&D Systems), 10 ng/ml insulin growth factor
1 (R&D Systems), 200 ng/ml ascorbic acid, 50 nM retinoic acid
(Sigma), and 1 mM dibutyryl cyclic AMP (Sigma), and cultured for
20 days. Glutamatewas added in the last 24 hr and sodiumarsenite
was added in the last 1 hr.
Immunocytochemistry
Immunocytochemistry was performed as described previously
(Imaizumi et al., 2015). Detailed conditions are given in the
Supplemental Information (Table S4). Fluorescence images wereCell Reports j Vol. 6 j 496–510 j April 12, 2016 j ª2016 The Authors 507
acquired on AxioVision (Zeiss), BZ-9000 (Keyence), or IN Cell
Analyzer (GE Healthcare).
High-Content Analysis
For the MPC population assay, neuronal subtype assay, neurite
length analysis and cleaved-CASPASE3 analysis, stained plates
were imaged on the high-content cellular analysis system IN
Cell Analyzer 6000 (GE Healthcare) and a set of 5 3 5 fields
were collected from each well using the 203 objective, resulting
in over 10,000 cells being scored per well. For FUS mis-localiza-
tion analysis and stress granule analysis, stained plates were
imaged on IN Cell Analyzer 6000 and a set of 6 3 6 fields
were collected from each well using the 603 objective, resulting
in over 9,000 cells being scored per well. Analysis (IN Cell
Developer Toolbox v1.9; GE Healthcare) began by identifying
intact nuclei stained by Hoechst, which were defined as traced
nuclei that were larger than 50 mm2 in surface area and with
intensity levels that were typical and lower than the threshold
brightness of pyknotic cells. Each traced nucleus region was
then expanded by 50% and cross-referenced with MPC markers
(OLIG2, SOX2 and ISLET1), motor neuron markers (ISLET1,
SMI32 and HB9), glutamatergic neuron marker (VGLUT1),
glutamate-responsive neuron marker (GLUR1), neuron markers
(MAP2 and bIII-TUBULIN), and pluripotent marker (OCT4) to
identify them; from these images, the percentages of these
were calculated. By setting areas on each cell type or neural
subtype, the ratio of FUS mis-localization into cytosol, the num-
ber of stress granules, or the number of FUS-positive stress gran-
ules in OCT4-positve iPSCs, bIII-TUBULIN-positive neurons or
HB9-positive motor neurons were analyzed. Using the above-
described traced images of each cell, neurite length and the
cleaved-CASPASE3-positive cell ratio in bIII-TUBULIN-positive
neurons or HB9-positive motor neurons were analyzed.
Quantitative RT-PCR
RNA was isolated using an RNeasy kit (Qiagen) and reverse
transcription using iScript cDNA Synthesis Kit (Bio-Rad). Quan-
titative RT-PCR was performed using SYBR Premix Ex Taq II
(TaKaRa) on the ViiA 7 Real-Time PCR System (Life Technolo-
gies) (Table S5).
Sequence Analysis
GenomicDNAwas isolated using aDNeasy kit (Qiagen) and ampli-
fied using intronic primers and direct nucleotide sequencing (Table
S5). Both sense and antisense strands of all amplicons were
sequenced using the Big Dye 3.1 dideoxy terminator methods
(Applied Biosystems) and ABI Prism 3130xL Genetic Analyzer
(Applied Biosystems).
Exon Array for MPCs
Exon array analysis was performed using an Affymetrix GeneChip
Human Exon 1.0 ST Array. Data were analyzed using the
GeneSpring GX7.3.1 software (Agilent), UCSC Genome browser
(http://genome.ucsc.edu/index.html), and DAVID Bioinformatics
Resources (http://david.abcc.ncifcrf.gov/). Exon array data have
been registered in the Gene Expression Omnibus under accession
number GEO: GSE76698.508 Stem Cell Reports j Vol. 6 j 496–510 j April 12, 2016 j ª2016 The AuthoSUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, seven figures, and five tables and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2016.
02.011.
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